Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 11, 2006. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding Ordinary Shares of the Company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of share transactions rather than a financial performance report.
Material Changes
The material change reported is a transfer of 124,779 Ordinary Shares from the GlaxoSmithKline Employee Trust ("the GSK Trust") to participants in the SmithKline Beecham Employee Share Option Plan 1991. This transaction occurred on September 9, 2006, and the Company was advised of it on October 10, 2006.
Management Commentary and Risks
The GSK Trust is identified as a discretionary trust where all current and former employees of GlaxoSmithKline plc and its subsidiaries are potential beneficiaries. Three directors—Dr J-P Garnier, Dr M M Slaoui, and Mr J S Heslop—are noted as having an interest in the shares held in the GSK Trust in the same capacity as other employees. The filing contains no specific guidance, outlook, or discussion of risks beyond the standard disclosure of the share transfer.
Key Facts for Investor Verification
- 124,779 Ordinary Shares were transferred from the GSK Trust to employee plan participants on September 9, 2006.
- Three directors (Dr J-P Garnier, Dr M M Slaoui, Mr J S Heslop) hold interests in the GSK Trust alongside other employees.
- The transaction was notified in accordance with Disclosure Rule 3.1.4R(1)(b).
- No financial performance data is included in this specific filing.